B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: Risk factors, treatment and outcome

Bone Marrow Transplantation

Volumn 23, Issue 3, 1999, Pages 251-258

  Gross, T G ^a,b   Steinbuch, M ^a   DeFor, T ^a   Shapiro, R S ^a   McGlave, P ^a   Ramsay, N K C ^a   Wagner, J E ^a   Filipovich, A H ^a,c  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

EBV; Lymphoproliferative disease; Outcome; Risk factors

Indexed keywords

ALPHA INTERFERON;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; INCIDENCE; LEUKAPHERESIS; LEUKEMIA REMISSION; LYMPHOPROLIFERATIVE DISEASE; MALE; MORTALITY; MULTIPLE REGRESSION; PRIORITY JOURNAL; RISK FACTOR; T LYMPHOCYTE;

EID: 0033060037     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701554     Document Type: Article

References (42)

1. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985; 39: 461-472.
2. Frizzera G, Hanto DW, Gajl-Peczalska KJ et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262-4279.
3. Swerdlow SH. Post-transplant lymphoproliferative disorders: a morphologic, phenotypic and genotypic spectrum of disease. Histopathology 1992; 20: 373-385.
4. Cohen JI. Epstein-Barr virus lymphoproliferative disease associated with acquired immune deficiency. Medicine 1991; 70: 137-160.
5. Henle G, Henle W. The virus as the etiologic agent of infectious mononucleosis. In: Epstein MA, Achong BG (eds). The Epstein-Barr Virus. Springer-Verlag: New York, 1979, pp 297-320.
6. Wallace LE, Rickinson AB, Rowe M, Epstein MA. Epstein-Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen. Nature 1982; 297: 413-415.
7. Pearson GR, Orr TW. Antibody-dependent lymphocyte cytotoxicity against cells experiencing Epstein-Barr virus antigens. J Natl Cancer Inst 1986; 56: 485-488.
8. Blazar BA, Patarroyo M, Klein E, Klein G. Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by superinfection or sodium butyrate. J Exp Med 1980; 151: 614-627.
9. Hasler F, Bluestein HG, Zvaifler NJ, Epstein LB. Analysis of the defects responsible for the impaired regulation of the Epstein-Barr virus-induced B cell proliferation by rheumatoid arthritis lymphocytes: I. Diminished gamma interferon production in response to autologous stimulation. J Exp Med 1983; 157: 173-188.
10. Mathur A, Kamat DM, Filipovich AH et al. Immunoregulatory abnormalities in patients with Epstein-Barr virus-associated B cell lymphoproliferative disorders. Transplantation 1994; 57: 1042-1045.
11. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New Engl J Med 1994; 330: 1185-1191.
12. Shapiro RS, McClain K, Frizzera G et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234-1243.
13. Zutter MM, Martin PJ, Sale GE et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520-529.
14. Ash RC, Casper JT, Chitambar CR et al. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. New Engl J Med 1990; 322: 485-494.
15. Fischer A, Blanche S, Le Bidois J et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. New Engl J Med 1991; 324: 1451-1456.
16. Witherspoon RP, Fisher LD, Schoch G et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. New Engl J Med 1989; 321: 784-789.
17. Antin JH, Bierer BE, Smith BR et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991; 78: 2139-2149.
18. Gerritsen EJA, Stam ED, Hermans J et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transplant 1996; 18: 377-382.
19. Kernan NA, Bortsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donor facilitated by the National Marrow Donor Program. New Engl J Med 1993; 28: 593-602.
20. Deeg HJ. Delayed complications after bone marrow transplantation. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, MA, 1994, pp 538-544.
21. Hale G, Waldmann H. Risks of developing EBV-LPD after T cell-depleted marrow transplantation. Blood 1998; 91: 3079-3083.
22. Henslee-Downey PJ. Choosing an alternative bone marrow donor among available family members. Am J Pediatr Hematol Oncol 1993; 15: 150-161.
23. Atkinson K, Farewell V, Storb R et al. Analysis of late infection after human bone marrow transplantation: role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-vs-host disease. Blood 1982; 60: 714-720.
24. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991; 78: 1373-1380.
25. Lucas KG, Small TN, Heller G et al. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996; 87: 2594-2604.
26. Meyers JD, Atkinson K. Infection in bone marrow transplantation. Clin Haematol 1983; 12: 791-811.
27. Bhatia S, Ramsay NKC, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633-3639.
28. d'Amore ES, Manivel JC, Gajl-Peczalska KJ et al. B-cell lymphoproliferative disorders after bone marrow transplant. Cancer 1991; 68: 1285-1295.
29. Gratama JW. Epstein-Barr virus infections in bone marrow transplantation recipients. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, MA, 1994, p 429-442.
30. Cen H, Breinig MC, Atchinson RW et al. Epstein-Barr virus transmission via the donor organs in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3 and 1R4. J Virol 1991; 65: 976-980.
31. Gratama JW, Oosterveer MA, Zwaan FE et al. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implication for sites of viral latency. Proc Natl Acad Sci USA 1988; 85: 8693-8696.
32. Haque T, Thomas JA, Falk KI et al. Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. J Gen Virol 1996; 77: 1169-1172.
33. Wagner JE, Donnenberg AD, Noga SJ et al. Lymphocyte depletion of donor bone marrow by counterflow centrifuged elutriation: results of a phase I clinical trial. Blood 1988; 72: 1168-1178.
34. Wagner JE, Santos GW, Noga SJ et al. Bone marrow graft engineering by counterflow centrifuged elutriation: results of a phase I-II clinical trial. Blood 1990; 75: 1370-1377.
35. Gross TG, Hinrichs SH, Davis JR et al. Depletion of Epstein-Barr virus (EBV) infected cells in donor marrow by counterflow elutriation. Exp Hematol 1998; 26: 395-399.
36. Filipovich AH. Stem cell transplantation from unrelated donors for correction of primary immunodeficiencies. Immunol Aller Clin N Am 1996; 16: 377-392.
37. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. New Engl J Med 1994; 331: 679.
38. Trigg ME, Alarcon P, Rumelhart S et al. Alpha-interferon therapy for lymphoproliferative disorders developing in two children following bone marrow transplants. J Biol Response Mod 1989; 8: 603-611.
39. Ho M, Jaffe R, Miller G et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988; 45: 719-727.
40. Lucas KG, Burton RL, Zimmerman SE et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998; 91: 3654-3661.
41. Rooney CM, Loftin S, Holladay MS et al. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995; 89: 98-103.
42. Heslop HE, Ng CYC, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Med 1996; 2: 551-555.